A-328 Diagnostic Value of Combined Detection of BDG assay and GM assay in Invasive Aspergillosis

Abstract Background With an increase in the number of patients who are immunosuppressed or immunocompromised there has been an increase in invasive fungal infection in the past few decades with its associated high morbidity and mortality, ranging from 60% to 90%. The role of early and accurate diagnosis in the aggressive containment of the fungal infection at the initial stages becomes crucial, preventing the development of a life-threatening situation. Conventional fungal identification depends on microscopic analysis and microorganism medium growth. Serological testing represents a quicker way of detecting the causal fungi, aiding in the diagnostic decision-making process. The advantage of performing serology-based tests is the rapid results obtained, unlike culture methods, and the non-invasive nature of the sample (i.e. blood, urine, sputum, etc.) while acting as a potential prognostic marker, for example, (1,3)-ß-D-glucan (BDG assay) and galactomannan(GM assay). Recently, a novel chemiluminescent immunoassay (CLIA) for BDG and GM from Dynamiker Biotechnology (Tianjin) Co., Ltd. was released as a screening test of invasive aspergillosis (IA). It is a fully automated assay with high throughput and short detection time. Here, we explored diagnostic value of combined detection of BDG-CLIA and GM-CLIA for IA. Methods A total of 114 patients were admitted from March 2023 to July 2023 were enrolled. According to 2019 EORTC/MSG definitions of invasive aspergillosis, they were divided into IA group (67 cases) and non-IA group (47 cases). The samples were tested in parallel using the Dynamiker BDG-CLIA and GM-CLIA. Results The sensitivity and specificity of GM-CLIA method were 86.57% and 82.98%, and that of G-CLIA method were 68.66% and 70.21%, respectively. Compared with BDG-CLIA alone or GM-CLIA alone, sensitivity of combined diagnosis for IA was significantly improved (92.53%, 95% CI: 82.74-97.22, P<0.05). Conclusion The combined deteclion of BDG-CLIA and GM-CLIA can effectively improve diagnostic sensitivity of IA patients, and can be used as an auxiliary diagnosis for invasive pulmonary fungal infection.